Internal Medicine

Psoriatic arthritis

Questions discussed in this category

Does the presence of psoriatic arthritis affect your decision to use an anti-IL-17 or IL-23 drug in your psoriasis patients?

3 Answers available

How would you manage active psoriasis and psoriatic arthritis in patient on Rituximab and prednisone for MPO positive vasculitis?

The patient has ongoing inflammatory arthritis despite methotrexate, apremilast, and jak inhibitor trials.

1 Answer available

How do you approach use of DMARDs and/or biologics for inflammatory arthritis in patients with a history of seizure disorder on anti-epileptic medications?

Is there any concern for drug interactions of DMARDs and/or biologics with anti seizure medications?

1 Answer available

How do you approach managing nausea and GI side effects when initiating methotrexate?

2 Answers available

How do you counsel patients on the risks and benefits of an IL-23 agent versus an IL-17A or IL-17A/F agent?

What side effects do you highlight in conversation with them? How do you approach toxicity monitoring?

2 Answers available

Do you avoid the use of hydroxychloroquine in patients with psoriasis and/or psoriatic arthritis?

1 Answer available

Would you consider using a JAK inhibitor in combination with an IL 23 inhibitor in cases of severe psoriasis, psoriatic arthritis, or axial spondyloarthritis that is refractory to multiple biologic DMARDs?

2 Answers available

What is your approach to using apremilast for psoriatic arthritis in patients with history of depression?

1 Answer available

How long would you recommend that a patient continues guselkumab prior to deciding that the therapy is not effective?

In contrast to TNF inhibitors for psoriatic arthritis, which seem to peak and maintain response percentages, the DISCOVER-2 Trial (McInnes et al., PMI...

4 Answers available

How do you interpret treatment response in the DISCOVER-2 Trial when patients were allowed to remain on up to 10mg of prednisone equivalent for disease control while on guselkumab?

In clinical practice continued steroid dependence is often seen as a reason to switch therapy and providers can be especially hesitant to use systemic...

3 Answers available

Where in the sequence of biologics would you consider guselkumab for patients with active psoriatic arthritis despite standard DMARD therapy?

Based on the results of the DISCOVER-2 Trial (McInnes et al., PMID 34719872), should guselkumab be used prior to anti-TNF therapy in these patients?

3 Answers available

What has been your experience using apremilast to treat mild to moderate psoriatic arthritis not controlled with NSAIDs?

1 Answer available

What disease activity measures do you find helpful in clinical practice for psoriatic arthritis/peripheral spondyloarthritis?

1 Answer available

Would you use an IL-17 inhibitor for a psoriatic arthritis patient with inactive inflammatory bowel disease?

1 Answer available

What is the preferred DMARD in active spondyloarthropathy with psoriasis and sacroiliitis features in the setting of treated hepatitis C with negative viral load?

In patients refractory to NSAIDs and sulfasalazine

1 Answer available

What are some strategies for radiographically differentiating between erosions secondary to erosive osteoarthritis versus psoriatic arthritis involving the DIP joints?

1 Answer available

How do you differentiate between axial psoriatic arthritis and axial spondylitis with psoriasis, and is it important to distinguish between these two conditions from a prognostic and treatment perspective?

1 Answer available

Papers discussed in this category

Arthritis & rheumatology (Hoboken, N.J.), 2016-05

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.

Arthritis Rheumatol, 2019 Oct

2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.

Rheumatology (Oxford),

Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis?

Rheumatology (Oxford),

Axial disease in psoriatic arthritis.

Clin. Exp. Rheumatol., 2016 Dec 13

Clinical and genetic associations of radiographic sacroiliitis and its different patterns in psoriatic arthritis.

Lancet, 2015 Oct 01

Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.

J Rheumatol Suppl,

GRAPPA 2018 Project Report.

Nat Rev Rheumatol,

Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison.

Rheumatology (Oxford),

Treatment guidelines in psoriatic arthritis.

Ann Rheum Dis, 2015 Dec 07

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.

J Med Imaging Radiat Oncol,

Gull-wing deformity: Osteoarthritis.

J Ultrason, 2016 Mar 29

Diagnostic imaging of psoriatic arthritis. Part I: etiopathogenesis, classifications and radiographic features.

Annals of the rheumatic diseases, 2017-04

International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials.

Arthritis Care Res (Hoboken), 2018 Aug

Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight-Control Clinical Trial and an Observational Cohort.

Arthritis Care Res (Hoboken),

Measuring Outcomes in Psoriatic Arthritis.

Arthritis Care Res (Hoboken), 2019 Jan

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

Arthritis Rheumatol, 2022 Feb 07

Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis.

The Journal of rheumatology, 2012-01

Combination biologic treatment of refractory psoriasis and psoriatic arthritis.

JAAD Case Rep, 2019 Oct 10

Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis.

Clinical rheumatology, 1988 Sep

Treatment of psoriatic arthritis with sulphasalazine: a one year open study.

Journal of the American Academy of Dermatology, 1987 Apr

Gold therapy and its indications in dermatology. A review.

Journal of the American Academy of Dermatology, 2020 May 19

Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment.

Annals of the rheumatic diseases, 2024 Mar 18

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.

Ann Rheum Dis, 2020 Dec 17

Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial.

Expert review of anticancer therapy, 2009-01

The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.

Lancet Gastroenterol Hepatol, 2023 Feb 01

Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.

Related Topics in Internal Medicine